Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short-term Investments (2016 - 2017)

Northwest Biotherapeutics' Short-term Investments history spans 4 years, with the latest figure at $397000.0 for Q1 2017.

  • Quarterly results put Short-term Investments at $397000.0 for Q1 2017, down 46.78% from a year ago — trailing twelve months through Mar 2017 was $397000.0 (down 46.78% YoY), and the annual figure for FY2016 was $685000.0, down 22.69%.
  • Short-term Investments for Q1 2017 was $397000.0 at Northwest Biotherapeutics, down from $685000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.0 million in Q2 2015 to a low of $397000.0 in Q1 2017.
  • The 4-year median for Short-term Investments is $806000.0 (2014), against an average of $779400.0.
  • The sharpest move saw Short-term Investments grew 2.43% in 2015, then plummeted 46.78% in 2017.
  • Year by year, Short-term Investments stood at $865000.0 in 2014, then rose by 2.43% to $886000.0 in 2015, then fell by 22.69% to $685000.0 in 2016, then crashed by 42.04% to $397000.0 in 2017.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $397000.0, $685000.0, and $685000.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.